Victory Capital Management Inc. Has $2.72 Million Position in Alnylam Pharmaceuticals, Inc. (ALNY)
Victory Capital Management Inc. lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,175 shares of the biopharmaceutical company’s stock after selling 2,850 shares during the period. Victory Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,723,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the stock. Crossmark Global Holdings Inc. bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $349,000. Fayerweather Charles bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $230,000. Aperio Group LLC increased its holdings in Alnylam Pharmaceuticals by 5.1% during the 3rd quarter. Aperio Group LLC now owns 16,908 shares of the biopharmaceutical company’s stock worth $1,987,000 after acquiring an additional 823 shares during the period. First Trust Advisors LP increased its holdings in Alnylam Pharmaceuticals by 25.3% during the 3rd quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock worth $92,185,000 after acquiring an additional 158,288 shares during the period. Finally, Fox Run Management L.L.C. bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $540,000. 92.73% of the stock is currently owned by institutional investors and hedge funds.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 74,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the completion of the sale, the chief executive officer now owns 223,710 shares of the company’s stock, valued at approximately $28,379,850.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the stock in a transaction on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now directly owns 45,201 shares of the company’s stock, valued at approximately $5,490,113.46. The disclosure for this sale can be found here. Insiders have sold a total of 289,797 shares of company stock valued at $34,422,712 in the last three months. 4.30% of the stock is currently owned by corporate insiders.
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) opened at $127.51 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83. Alnylam Pharmaceuticals, Inc. has a 12-month low of $35.98 and a 12-month high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The company’s quarterly revenue was up 24.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.21) EPS. sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -5.33 earnings per share for the current fiscal year.
A number of analysts recently weighed in on ALNY shares. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. BMO Capital Markets reaffirmed an “outperform” rating and set a $99.00 target price (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 6th. Instinet started coverage on shares of Alnylam Pharmaceuticals in a report on Friday, September 15th. They set a “reduce” rating and a $56.00 target price on the stock. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $110.00 target price (down previously from $126.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Finally, Leerink Swann reissued a “market perform” rating and issued a $72.00 price target (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, September 8th. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $121.85.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.